NDA 019430 · Viatris
Epipen E Z Pen
Epinephrine · Intramuscular, Intramuscular, Subcutaneous · alpha-Adrenergic Agonist; beta-Adrenergic Agonist; Catecholamine
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Dec 22, 1987
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,347
454 Phase 3, 232 recruiting
FAERS reports
65,115
37,014 serious, 4,036 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 12, 2026.
Epinephrine injection, USP auto-injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Epinephrine injection, USP auto-injectors are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Anaphylactic reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema. Epinephrine injection, USP auto-injectors are intended for immediate administration as emergency supportive therapy only and are not a substitute for immediate medical care. Epinephrine injection, USP auto-injector is a non-selective alpha and beta-adrenergic receptor agonist indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis. ( 1 )
Mechanism: Epinephrine acts on both alpha- and beta-adrenergic receptors.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 22, 1987 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
- EPIPEN E Z PEN · EPINEPHRINE 0.3MG/DELIVERY · INJECTABLE, INTRAMUSCULAR · Discontinued
- EPIPEN · EPINEPHRINE 0.3MG/DELIVERY · INJECTABLE, INTRAMUSCULAR, SUBCUTANEOUS · Prescription · TE AB
- EPI E Z PEN JR · EPINEPHRINE 0.15MG/DELIVERY · INJECTABLE, INTRAMUSCULAR · Discontinued
- EPIPEN JR. · EPINEPHRINE 0.15MG/DELIVERY · INJECTABLE, INTRAMUSCULAR, SUBCUTANEOUS · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Epinephrine" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Platform of Randomized Adaptive Clinical Trials in Critical IllnessPivotal-lookingRecruiting
University Health Network, TorontoAcademic, hospital or other
NCT05440851 · 6,250 participants (planned) · Start Apr 30, 2023 · Primary completion Mar 31, 2027
Drug: Early Cohort corticosteroid dose; Extended Cohort corticosteroid dose and 6 more · For: Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
Sites: Tucson, Arizona; Los Angeles, California; San Diego, California · 103 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19Pivotal-lookingStatus unknown
Huashan HospitalAcademic, hospital or other
NCT05855395 · 5,815 participants (planned) · Start May 26, 2023 · Primary completion May 1, 2024
Drug: Glucocorticoid · For: COVID-19
Sites: Fuzhou, China; Quanzhou, China; Guangzhou, China · 15 sites in all
- Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological OutcomePivotal-lookingNot yet recruiting
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT07442071 · 4,336 participants (planned) · Start Jun 2026 · Primary completion Jul 2030
Drug: Epinephrine 0.5 mg intravenous bolus; Epinephrine 1 mg intravenous bolus · For: Out-of-hospital Cardiac Arrest (OHCA)
Sites: Annecy, France; Bayonne, France; Besançon, France · 26 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective5,929
- headache4,422
- fatigue4,074
- sinusitis4,052
- dyspnoea3,477
- nausea3,396
- pain3,365
- product dose omission issue3,247
- off label use2,904
- pneumonia2,668
- covid-192,631
- cough2,285
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 160 |
| 2005 | 146 |
| 2006 | 167 |
| 2007 | 233 |
| 2008 | 352 |
| 2009 | 360 |
| 2010 | 536 |
| 2011 | 1,018 |
| 2012 | 819 |
| 2013 | 713 |
| 2014 | 1,430 |
| 2015 | 2,554 |
| 2016 | 6,749 |
| 2017 | 3,571 |
| 2018 | 3,419 |
| 2019 | 4,195 |
| 2020 | 7,414 |
| 2021 | 4,941 |
| 2022 | 4,661 |
| 2023 | 4,945 |
| 2024 | 5,804 |
| 2025 | 6,158 |
| 2026 | 4,767 |
Recalls
7 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Mar 12, 2017 · Class I · Ongoing
Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication
Mar 12, 2017 · Class I · Ongoing
Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.
Shaker MS, Wallace DV, Golden DBK, et al. · J Allergy Clin Immunol 2020 · Meta-Analysis, Systematic Review
- OUTCOMES OF PEDIATRIC FLUID-REFRACTORY SEPTIC SHOCK ACCORDING TO DIFFERENT VASOACTIVE STRATEGIES: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Marchetto L, Zanetto L, Comoretto RI, et al. · Shock 2024 · Systematic Review, Meta-Analysis
- Vasopressors during adult cardiac arrest: A systematic review and meta-analysis.
Holmberg MJ, Issa MS, Moskowitz A, et al. · Resuscitation 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.
Levy B, Clere-Jehl R, Legras A, et al. · J Am Coll Cardiol 2018 · Comparative Study, Multicenter Study
- A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest.
Perkins GD, Ji C, Deakin CD, et al. · N Engl J Med 2018 · Multicenter Study, Randomized Controlled Trial
- Therapeutic effects of vasopressin on cardiac arrest: a systematic review and meta-analysis.
Yan W, Dong W, Song X, et al. · BMJ Open 2023 · Meta-Analysis, Systematic Review
Sponsor: Viatris · Also marketed as Epipen, Epi E Z Pen Jr, Epipen Jr.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.